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Summary of the Habilitation-thesis 
 
The AcrA/AcrB/TolC protein complex is the major drug resistance pump of Escherichia coli. It 
mediates the proton-motive force driven efflux of diverse substrates, such as bile salts, detergents, 
organic solvents and many structurally unrelated antibiotics. AcrB is a member of the Resistance 
Nodulation cell-Division (RND) superfamily, which includes the human homologues Niemann Pick 
transporter type C1 and the hedgehog receptor Patched.  
 
AcrB forms a trimer that is located in the inner membrane and is, within the tripartite complex, 
responsible for substrate selectivity and energy transduction. The newly elucidated asymmetric 
structure of trimeric AcrB at 2.9 Å resolution reveals three different monomer conformations 
representing consecutive states in a transport cycle. The monomers show tunnels with occlusions at 
different sites leading from the lateral side through the periplasmic pore domains towards the funnel of 
the trimer and TolC. The structural changes create a hydrophobic pocket in one monomer, which is not 
present in the other two monomers. Minocyclin, an AcrB substrate, specifically binds to this pocket 
substantiating its role as drug binding pocket. 
  
The energy transduction from the proton motive force into drug efflux includes proton binding in (and 
release from) the transmembrane part. The conformational changes observed within a triad of essential, 
titratable residues (Asp407/Asp408/Lys940) residing in the hydrophobic transmembrane domain 
appears to be associated with the conformational changes seen in the periplasmic domain.  
 
From the asymmetric structure a possible peristaltic pump transport mechanism based on a functional 
rotation of the AcrB trimer is postulated. The novel transport model merges Jardetzky’s alternate 
access pump mechanism with the rotating site catalysis of F1Fo ATPase and suggests a working 
hypothesis for the transport mechanism of RND transporters. The proposed structural changes 
underlying the functional rotation of AcrB were investigated by introduction of engineered disulfide 
cross-links. Double cysteine substituted AcrB mutants residing in the native membrane of E. coli formed 
disulfide linkages between subdomains if the distances were small enough to allow chemical bonding in 
agreement with the asymmetric structure. Movement constraints of cross-linked subdomains lead to a 
significant loss of pumping activity, which could be restored upon reduction of the disulfide bond.  
 
Scope of the findings: From bacteria to man 
A defect human homologue of AcrB causes the Niemann-Pick disease type C1 
The RND superfamily includes members from all kingdoms. One (in)famous human AcrB homologue is 
the Niemann-Pick type protein C (NPC1), thought to be involved in the transport of cholesterol out of 
the lysosomes. A defect in the gene encoding this protein results in accumulation of unesterified 
cholesterol in the endosomal/lysosomal compartment, leading to neurodegeneration and death during 
early childhood. Despite considerable research efforts, the physiological function and its exact role in 
the cholesterol distribution has not yet been elucidated.  
 
RND superfamily member Patched (Ptc) is involved in hedgehog signaling  
Another human homologue and RND superfamily member is Patched (Ptc) which is involved in 
hedgehog signaling linked to cell growth and differentiation. Dysfunction of the hedgehog signaling 
pathway causes tumor initiation and growth. Patched is involved in sequestering Hedgehog (Hh) by 
which it is inactivated. Inactivation of Ptc leads to activation of the 7 transmembrane G protein-coupled 
receptor Smoothened (Smo) which tranduces the Hh signal to the cytoplasm. The current hypothesis 
envisions endogenous metabolites like oxysterol derivatives and vitamin D3 derivatives to be mediators 
of the Hh signal via the activity of Ptc and Smo. Ptc would thereby act as a pump for (pro-)vitamin D3 
(or for a highly similar molecule) which inactivates Smo upon binding (no signal). Hh inhibition of Ptc 
would lead to reduction of the vitamin D3 repressor, activation of Smo and induction of the Hh signaling 
pathway to the cytoplasm. 
 
The molecular insights gained from the prokaryotic AcrB efflux system with respect to the 
chemiosmotic energy coupling of solute transport provide a basis for the understanding of the 
mechanisms of transport for human NPC1 and Ptc. 
Introduction 
Multidrug resistance is a serious threat in the fight against cancer and microbial infections. This 
resistance is often associated with the overproduction of membrane transport proteins that are capable to 
extrude chemotherapeutics, antibiotics, detergents, dyes and organic solvents. In mammalian tumor 
cells, overproduction of the ATP-dependent P-glycoprotein (ABCB1) leads to multiple drug resistance 
and considerable research efforts are directed to the elucidation of the transport mechanism of this 
protein1.  
In prokaryotic cells, proton motive force-dependent transporters are often found to be responsible for 
drug resistance. In Gram-positive bacteria, drug resistance is often conferred by members of the major 
facilitator superfamily2, whereas in Gram-negative bacteria such as Escherichia coli and Pseudomonas 
aeruginosa, tripartite multidrug efflux systems extrude a large variety of cytotoxic substances from the 
cell membrane directly into the medium bypassing the periplasm and the outer membrane.  
In E. coli, the tripartite efflux system AcrA/AcrB/TolC (Figure 1) is the pump in charge of the efflux of 
dyes, bile salts, detergents and multiple antibiotics including fluoroquinolones (e.g. ciprofloxacin), 
macrolides (e.g. erythromycin), tetracyclins (e.g. minocyclin), phenylpropanoids (e.g. chloramphenicol) 
and β-lactams (e.g. oxacillin)3-8 (Figure 2). The trimeric outer membrane factor (OMF) TolC forms a β-
barrel pore in the outer membrane and exhibits a long periplasmic α-helical conduit. The TolC channel 
is docked co-axially9,10 onto the trimeric resistance nodulation division (RND) proton/drug antiporter 
AcrB, which is located in the inner membrane and is responsible for drug specificity and energy 
transduction. The membrane fusion protein (MFP) member AcrA appears to directly interact with AcrB 
and TolC and fulfills the role as an adaptor protein9,11,12. This tripartite setup promotes a drug transport 
mode in which the drug substrates are transported from the membrane to the outside through a 
continuous confined pathway established by AcrB and TolC (Figure 1).  
The efflux of the toxic compounds across two membranes in Gram-negative bacteria results, in 
combination with the low permeability of the outer membrane, in a synergistically increased resistance 
towards the drug. Hence, inactivation of the efflux pump or permeabilization of the outer membrane of 
the bacterium results in hyper-susceptibility to various drugs13. 
The question about the functional origin of these efflux systems in Gram-negative bacteria is still a 
matter of debate. It has been proposed that the efflux of bile salts allows the survival of Gram-negative 
bacteria in the gut14, or that such efflux systems relieves the cell of toxic metabolites such as indole or 
from products of membrane and murein recycling15,16. More recently, the AcrA/AcrB/TolC efflux 
system was postulated to transport molecules mediating signals for quorum sensing17. An important 
question arises with respect to the broad substrate specificity and how the efflux system prevents 
transport of essential hydrophobic cofactors (e.g. flavins) or phospholipids out of the cell. 
 Figure 1 Schematic drawing of the tripartite multidrug efflux system AcrA/AcrB/TolC. 
AcrB (proton/drug antiporter, RND component) resides in the inner membrane and is responsible for 
substrate recognition and energy transduction. Drugs are captured at the inner or outer leaflet of the 
inner membrane and extruded in a coupled exchange with protons. TolC (outer membrane channel, 
OMF component) forms a pore in the outer membrane and exhibits a long periplasmic conduit. AcrA 
(membrane fusion protein, MFP component) is postulated to mediate contact between AcrB and TolC. 
 
Another line of investigation is the specific inhibition of these transporters by non-antibiotic compounds. 
Quite recently, inhibitors of the AcrA/AcrB/TolC and the and the MexA/MexB/OprM efflux systems 
like Phe-Arg-β-naphthylamide or arylpiperazines are postulated to inhibit the efflux of other substrates 
by high affinity competitive binding to the drug binding pocket18,19.  
RND/MFP/OMF efflux systems have been recognized as a major health problem as they play a central 
role in multiple antibiotic resistance of pathogenic Gram-negative bacteria such as Campylobacter 
jejuni, E. coli, Klebsiella pneumoniae, P. aeruginosa and Salmonella enterica serovar typhimurium 
(reviewed in20,21). Highly resistant strains usually arise due to higher expression of the efflux pumps 
caused by mutations of regulatory proteins directly acting as repressors of transcription of the 
MFP/RND loci (e.g. AcrR) or indirectly by repressing the expression of upstream transcriptional 
activators (e.g. MarR repressing MarA)22.  
 
  
Figure 2 Substrates and inhibitors of the AcrA/AcrB/TolC efflux system. 
The system confers resistance to a wide variety of noxious substances like dyes, different classes of 
antibiotics, detergents, bile salts and small organic molecules. Phe-Arg-β-naphthylamide and 1-(1-
naphthylmethyl)-piperazine (NMP) inhibit RND efflux systems. 
 
The RND superfamily includes members from all kingdoms4. One (in)famous human AcrB homologue 
is the Niemann-Pick type protein C (NPC1), thought to be involved in the transport of cholesterol out of 
the lysosomes23. A defect in the gene encoding this protein results in accumulation of unesterified 
cholesterol in the endosomal/lysosomal compartment, leading to neurodegeneration and death during 
early childhood24. Despite considerable research efforts, the physiological function and its exact role in 
the cholesterol distribution has not yet been elucidated.  
 
Another human homologue and RND superfamily member is Patched (Ptc) which is involved in 
hedgehog signaling linked to cell growth and differentiation25. Dysfunction of the hedgehog signaling 
pathway causes tumor initiation and growth. Patched is involved in sequestering Hedgehog (Hh) by 
which it is inactivated. Inactivation of Ptc leads to activation of the 7 transmembrane G protein-coupled 
receptor Smoothened (Smo) which tranduces the Hh signal to the cytoplasm26. The current hypothesis 
envisions endogenous metabolites like oxysterol derivatives and vitamin D3 derivatives to be mediators 
of the Hh signal via the activity of Ptc and Smo27,28. Ptc would thereby act as a pump for (pro-)vitamin 
D3 (or for a highly similar molecule) which inactivates Smo upon binding (no signal). Hh inhibition of 
Ptc would lead to reduction of the vitamin D3 repressor, activation of Smo and induction of the Hh 
signaling pathway to the cytoplasm. 
 
The molecular insights gained from the prokaryotic AcrB efflux system with respect to the 
chemiosmotic energy coupling of solute transport provide a basis for the understanding of the 
mechanisms of transport for human NPC1 and Ptc. 
Summary of the collected papers 
The collected papers presented in this Habilitations-thesis describe the overproduction, purification, 
crystallization, X-ray crystallography and biochemical characterization of the Resistance Nodulation cell 
Division (RND) inner membrane transporter AcrB of E. coli. The first structure of a symmetric AcrB 
trimer was obtained at 3.5 Å resolution. A new 2.9 Å structure of trimeric AcrB in an asymmetric 
conformation was derived from crystals grown under different crystallization conditions and showed 
three structurally different monomers, postulated to represent consecutive steps of a transport cycle. 
Tunnels penetrating the periplasmic part in different ways suggest alternating access to a hydrophobic 
drug binding pocket, which is open in one of the three monomers and closed in the two other monomers. 
From this structure a possible peristaltic pump transport mechanism based on a functional rotation of the 
AcrB trimer is postulated. The novel transport model merges Jardetzky’s alternate access pump 
mechanism with the rotating site catalysis of F1Fo ATPase and suggests a working hypothesis for the 
transport mechanism of RND transporters. The proposed structural changes underlying the functional 
rotation of AcrB were investigated by introduction of engineered disulfide cross-links. Double cysteine 
substituted AcrB mutants residing in the native membrane of E. coli formed disulfide linkages between 
subdomains if the distances were small enough to allow chemical bonding in agreement with the 
asymmetric structure. Movement constraints of cross-linked subdomains lead to a significant loss of 
pumping activity, which could be restored upon reduction of the disulfide bond.  
 
Detailed description of the collected papers 
 
Symmetric and asymmetric structure of the AcrB trimer 
The first structure of the symmetric AcrB trimer was obtained at 3.5 Å resolution from crystals grown in 
a trigonal space group assigned as R3229-32. An AcrB monomer contains twelve transmembrane α-
helices (TM1 to TM12)(Figure 3A, D). TM4 and TM10 are surrounded by the other transmembrane 
helices of the monomer and harbour the residues K940 (TM10) and D407 and D408 (TM4), which 
appear to play an essential role in proton translocation30,33-35 (Figure 3D). The periplasmic part of the 
AcrB trimer consists of the TolC docking domain (DN and DC subdomains), located most distant from 
the membrane plane and the pore domain, and made up of subdomains PN1, PN2, PC1, and PC2 (Figure 
3A, C). The TolC docking domain exhibits a funnel-like structure narrowing to a central pore located in 
the pore domain. The central pore structure consists of three α-helices (designated pore helices), donated 
by the PN1 subdomains of each AcrB monomer (Figure 3B, C). At the proximal end of the central pore, 
a central cavity is present and extends to a 35 Å wide, transmembrane cavity (proposed to be filled with 
phospholipids) defined by the ring-like arrangement of the TM helices of the trimer (Figure 3A, D). 
Three vestibules at the monomer interface located just above the membrane plane lead towards the 
central cavity (Figure 3A).  
 Figure 3 (A) Backbone ribbon diagram side view of symmetric AcrB trimer. From top to bottom: the 
TolC docking domain includes a funnel-like structure.  It narrows to a central pore located in the pore 
domain. The transmembrane domain confines a central cavity.  (B) Top view from the periplasm along 
the crystallographic three-fold axis. The intermonomer-connecting loop protruding from one monomer 
into the next provide the main interaction within the AcrB trimer. (C) View as in (B) but the TolC 
docking domain has been removed. Subdomains PN1, PN2, PC1 and PC2 are indicated. The lateral 
cleft between subdomains PC1 and PC2 is suggested to accommodate AcrA. (D) Topology of the 
transmembrane helices top view along the crystallographic three-fold axis. The three monomers enclose 
a 30-35 Å wide central cavity. The TM4 and TM10 helices are surrounded by the other TM helices in 
each monomer and contain the titratable residues Asp407, Asp408 (TM4) and Lys940 (TM10). The 
structurally identical protomers (A-D) are individually coloured. 
 
We observed merohedral twinning of crystals grown in the trigonal space group. A high twinning 
fraction results in a blurred electron density, which cannot be computationally deconvoluted, and 
explains the difficulties encountered with this crystal form and led us to pursue the structure from 
different crystal forms. We solved a structure of trimeric AcrB determined at 2.9 and 3.0 Å resolution in 
space groups (C2, P1) which do not entail three-fold symmetry of the trimer. In contrast to the 
symmetric structure, this asymmetric structure reveals three different monomer conformations 
representing consecutive states in a transport cycle, designated loose (L), tight (T) and open (O) (Figure 
4). The structural changes create a hydrophobic pocket in the T monomer, which is not present in the L 
and O monomers. Minocyclin, an AcrB substrate, specifically binds to this pocket substantiating its role 
as drug binding pocket (ref. 35 and Seeger, Eicher, Sennhauser, Grütter, Pos, unpublished observations). 
The AcrB monomers show tunnels with occlusions at different sites leading from the lateral side through 
the pore domains towards the funnel of the trimer and TolC (Figure 5). From these structures we 
postulate a possible peristaltic pump transport mechanism based on a functional rotation of the trimer. 
 
A B C 
  
Figure 4 Main structural differences of the AcrB monomers. The three AcrB monomers, shown in 
cylinder representation in blue (loose, L), yellow (tight, T) and red (open, O), are superimposed onto the 
symmetric AcrB trimer model, which is depicted in transparent grey. a) A side view superimposition of 
the entire AcrB asymmetric trimer (coloured) and symmetric AcrB (transparent grey). b) A top view 
superimposition of the pore domain of the asymmetric and symmetric AcrB trimer structure. The 
structural changes in the T monomer create a hydrophobic pocket (yellow space fill model) in the 
PN2/PC1 subdomain interface, which is closed in the L (blue space fill model) and O (red) monomers. 
 
 
 
 
Figure 5 Upper panel: Visualisation of tunnels in the pore domain of the trimeric AcrB peristaltic drug 
efflux pump. The AcrB monomers are presented in a) blue (loose, L), b) yellow (tight, T) and c) red 
(open, O). The tunnels are highlighted as green surfaces in a ribbon model of the AcrB trimer. Lower 
panel: the putative proton translocation site with conserved residues D407, D408 (TM4) and K940 
(TM10) in the three monomers is depicted as viewed from the cytoplasm with 2Fo-Fc electron density 
map countoured at 0.5 σ (a) or 1 σ (b, c) superimposed. In the L (a) and T monomers (b) the same 
conformation is observed, whereas in the O monomer (c) K940 forms a salt bridge with D407. This 
interaction seems to be stabilised by hydrogen bonding of T978 (TM11). 
 
 
 
Proton translocation pathway and energy transduction 
The large conformational changes observed in the periplasmic part of this protein coincide with more 
subtle changes in the transmembrane domain. In the transmembrane domain of AcrB, TM4 and TM10 
are surrounded by the other transmembrane helices of the monomer and harbour the residues K940 
(TM10), D407 and D408 (TM4). As AcrB is energised by the proton-motive force, transient protonation 
of titratable groups within the transmembrane domain of the protein can be expected to be the 
mechanism which delivers the energy required for the conformational changes described above. Indeed, 
we observe a prominent K940 (TM10) side chain reorientation away from D408 and towards D407 
(both on TM4) in the O conformation (Figure 5, lower panel), and a bulging of TM5 towards TM4 and 
TM10, strengthening the hypothesis that this part of the transmembrane domain is central to proton 
binding and release.  
 
Engineered disulfide bonds in support of the functional rotation mechanism 
The functional rotation mechanism postulates conformational changes in the periplasmic pore domain 
through movements of subdomains during cycling of the monomers through the different states L, T and 
O. We introduced cysteine residues at the interfaces of potentially moving subdomains leading to 
disulfide bond formation, as quantified by alkylation of free cysteines and subsequent MALDI-TOF 
mass spectrometry analysis. Inhibition of the pump function due to cross-linking of these subdomains 
was shown by the increased susceptibility of E. coli for noxious compounds and by the reduction of N-
phenylnaphtylamine efflux. Most importantly, regain of function for the impaired mutants was obtained 
upon exposure to the reducing agent dithiothreitol. The results endorse the presence of the asymmetric 
AcrB trimer in the E. coli membrane and are in support of functional rotation within the trimer due to 
the cycling of the monomers through the different conformational states L, T and O. 
 
Future prospects 
Fighting infectious diseases will be a major challenge for the 21st century. The renewal of outbreaks of 
tuberculosis and cholera and the pronounced resistance of these and other common pathogenic bacteria 
towards most antibiotics will pose a major threat to the modern world. Besides the clinical and medical 
relevance of future research on these efflux systems, the elucidation of structures of membrane proteins 
in general and conducting following up experiments on a biochemical level is essential for 
understanding the basic mechanism of energy transduction and transport of molecules through the 
membrane. An extension of the structural (and functional) studies to mammalian homologues involved 
in disease and cancer (e.g. NPC1 and Ptc) is not only of medical but also of methodological interest and 
should be pursued accordingly.  
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